A phase 3, global, multi-center, double-blind, randomized, efficacy study of IMAB362 Plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) Adenocarcinoma. SPOTLIGHT.
- Strickland, Andrew (Primary Chief Investigator (PCI))
Project: Research